Poor
Not Aligned
Patient Risk:
Low
Summary
AI claims are largely generic about excipients and inactive ingredients, but there is no supporting information in the provided FDA label excerpts about excipient categories/typical ingredients. Therefore most claims are unsupported by the supplied labeling text.
Category Scores
Accurate Statements
Unsupported Statements
Albendazole is the active drug substance in albendazole products.
The provided ALBENZA label excerpts do not explicitly state that albendazole is the active drug substance (or otherwise describe active ingredient status in terms of product composition).
Non-active ingredients (excipients) may be present on albendazole product labels, including fillers, binders, coating agents, or sweeteners.
No provided label excerpt describes excipient categories (fillers, binders, coating agents, sweeteners) or their presence on labels.
Inactive ingredients vary by manufacturer and formulation.
No provided label excerpt addresses variability of inactive ingredients by manufacturer/formulation.
Common categories of inactive ingredients in albendazole products include fillers or diluents.
No provided label excerpt lists or discusses fillers/diluents as inactive ingredient categories.
Common categories of inactive ingredients in albendazole products include binders.
No provided label excerpt lists or discusses binders as inactive ingredient categories.
Common categories of inactive ingredients in albendazole products include coating materials for tablets.
No provided label excerpt discusses tablet coating materials as inactive ingredient categories.
Common categories of inactive ingredients in albendazole products include disintegrants.
No provided label excerpt lists or discusses disintegrants as inactive ingredient categories.
Common categories of inactive ingredients in albendazole products include flavoring/sweetening agents.
No provided label excerpt lists or discusses flavoring/sweetening agents as inactive ingredient categories.
Common categories of inactive ingredients in albendazole products include suspending agents for oral liquids.
No provided label excerpt discusses excipient categories for oral liquids; the provided formulation information is for ALBENZA tablets (200 mg) only.
Contradictions
Important Omissions
No label-referenced statements about FDA-approved indications, dosing, contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, monitoring, administration instructions, or specific populations were provided.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Claims relate to excipient generalities and active ingredient identification, with no dosing or safety recommendations. However, they are unsupported by the provided label excerpts, reducing informational reliability.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Most statements about excipient categories and variability are not supported by the provided ALBENZA prescribing-information excerpts.
Suggested Improvement
Limit claims to information explicitly present in the provided label excerpts (e.g., indications, dosing instructions, contraindications, warnings, interactions). For excipients, use the exact label 'Inactive ingredients' section (not provided here) or avoid speculative excipient-category statements.